Peter Attia· MD
if you look at it from a scientific standpoint that you could take that patient population and achieve that outcome I think it's one of the most remarkable things in cardiovascular medicine
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
if you look at it from a scientific standpoint that you could take that patient population and achieve that outcome I think it's one of the most remarkable things in cardiovascular medicine
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
PCSK9 Inhibitors as a class of drug have been perhaps the most exciting drug class introduced in the last decade um and the results have lived up to the hype